Guidance for Coronary Patients With ASA/NSAID Sensitivity

Share this content:
Guidance for Coronary Patients With ASA/NSAID Sensitivity
Guidance for Coronary Patients With ASA/NSAID Sensitivity

MONDAY, Oct. 24, 2016 (HealthDay News) -- In patients with stable chronic ischemic heart disease (CIHD) and histories of nonsevere hypersensitivity reactions to acetylsalicylic acid (ASA)/nonsteroidal anti-inflammatory drugs (NSAIDs), an ASA challenge is recommended, according to a study published online Oct. 12 in Allergy.

Gabriele Cortellini, M.D., from Rimini Hospital in Italy, and colleagues analyzed data on ASA challenges and desensitizations from 10 allergy centers (310 patients) and sought consensus from physicians and an expert panel to determine clinical criteria for eligibility for an ASA challenge and/or desensitization in coronary artery disease patients with hypersensitivity to ASA.

The researchers found that 119 of the 310 subjects had index reactions to ASA doses lower than 300 mg. Of the 138 with acute coronary syndrome (ACS), 101 underwent desensitizations. Of the 172 with CIHD, 126 underwent challenges. In all, 163 subjects underwent challenges and 147 underwent desensitizations; in the latter group, 86 had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges (seven at doses ≤500 mg; three at a cumulative dose of 110 mg). The desensitization failure rate was 1.4 percent.

"In patients with stable CIHD and histories of non-severe hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable," the authors write. "Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Basivertebral Nerve Ablation Beneficial for Chronic Back Pain

Basivertebral Nerve Ablation Beneficial for Chronic Back Pain

Improvement in self-reported outcomes at three months in patients with chronic lumbar back pain

FDA Approves Trulance for Chronic Idiopathic Constipation

FDA Approves Trulance for Chronic Idiopathic Constipation

Drug designed to stimulate secretion of intestinal fluid

ECG Could Be Used As Password for E-Health Record Access

ECG Could Be Used As Password for E-Health ...

Researchers say heartbeat could serve as a secure 'password' for patient's electronic medical history

is free, fast, and customized just for you!

Already a member?

Sign In Now »